Fourth Quarter & Full Year 2022 Financial & Business Update
Commercial Portfolio Expansion Opportunities Well Underway - All
Four with Positive Growth Potential
ČADCET
ADCETRIS
PADCEV
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials
MUC
HL
brentuximab vedotin for Injection
PTCL
HL
Foundation of care
for CD30-expressing lymphomas,
CTCL
PTCL
with survival data and under
DLBCL
U.S. SOC in second-line +
urothelial cancer with goal of
encompassing all lines of bladder
MIBC
NMIBC
2L MUC
evaluation in r/r DLBCL
CTCL
cancer
"TUKYSA
tucatinib
50 mg 150 mg tablets
Best-in-class TKI for HER2+ BC,
and first FDA-approved treatment
in HER2+ mCRC with ongoing trials
in earlier stage disease and other
solid tumors
Current*
Future Potential**
Current*
Future Potential**
HER2+
MBC
tivdak
tisotumab vedotin-tftv
for injection 40 mg
Metastatic
Cervical
HER2+
MCRC
2L HER2+ mBC
2L HER2+ mCRC
Adjuvant
First-in-class ADC for cervical
cancer providing important option
in high unmet need setting and
further opportunities
2L
Metastatic
Cervical
H&N
Current*
Future Potential**
Bars represent relative size of the addressable market (both current and potential
future) within each brand, but not between brands. For all bars, potential addressable
Seagen population is not indicative of current or expected market penetration. For illustrative
purposes only.
Current*
Future Potential**
*Addressable U.S. patient population based on current indications
**Potential addressable U.S. patient population based on ongoing trials. The safety and efficacy of these products have not
been established in these future potential indications, and future regulatory approval or commercial availability is not guaranteed.
9View entire presentation